Joseph Payne compensation by year
Arcturus Therapeutics Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $384,000 | $425,000 | $450,000 | $500,000 | $600,000 | $630,000 | $698,000 | $695,000 | $750,000 |
| Bonus | $40,810 | $372,532 | $243,000 | $450,000 | $360,000 | $504,000 | $208,500 | $367,000 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $0 | $636,888 | $472,818 | $11,911,500 | $0 | $4,460,000 | $3,986,000 | $2,635,000 | $941,000 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $23,955 | $1,252,624 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total | $448,765 | $2,687,044 | $1,165,818 | $12,861,500 | $960,000 | $5,594,000 | $4,892,500 | $3,697,000 | $1,691,000 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcturus Therapeutics Holdings Inc. DEF 14A filed April 24, 2026, accession 0001193805-26-000507, and prior-year filings.
How this page was built: the Arcturus Therapeutics Holdings Inc. filed document, accession 0001193805-26-000507. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 147,000 | — | $16.24 |
| Option | 100,000 | — | $28.88 |
| Option | 62,500 | — | $16.92 |
| Option | 175,000 | — | $6.52 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Arcturus Therapeutics Holdings Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Arcturus Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Joseph Payne · this page | President and Chief Executive Officer, Director | $1,691,000 |
| Andy Sassine | Former Chief Financial Officer | $1,181,500 |
| Padmanabh Chivukula | Chief Scientific Officer, Chief Operating Officer | $862,000 |
| Lance Kurata | Chief Legal Officer | $830,000 |
| Joe Roberts | Interim Principal Financial and Accounting Officer; Controller | $273,580 |
Board service
Arcturus Therapeutics board · FY2023–FY2025How this board is paid
Company policy: Arcturus Therapeutics pays directors a $50,000 cash retainer. As stated in Arcturus Therapeutics's FY2025 proxy.
The full Arcturus Therapeutics compensation record
free company briefThis page is one person within Arcturus Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Arcturus Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arcturus Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcturus Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.